Počet záznamov: 1
rituximab
SYS d000069283 LBL 00000ny--a2200181n--4500 005 20250606221744.2 008 160101|-|anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D12.776.124.486.485.114.224.075.785 065 $a D12.776.124.790.651.114.224.075.785 065 $a D12.776.377.715.548.114.224.284.785 066 $a 01 $c 03 150 $a rituximab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a CD20 protilátka, rituximab $2 slo 450 $w v $a IDEC-C2B8 protilátka $2 slo 450 $w v $a GP2013 $2 slo 550 $7 sllk_us_auth*d018951 $Y Antigens, CD20 $w b $a antigény CD20 550 $7 sllk_us_auth*d007155 $Y Immunologic Factors $w P $a faktory imunologické 550 $7 sllk_us_auth*d018501 $Y Antirheumatic Agents $w P $a antireumatiká 550 $7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické 550 $7 sllk_us_auth*d018951 $Y Antigens, CD20 $w p $a antigény CD20 665 $a 2016 (1995) $2 eng 680 9-
$i A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. $2 eng 750 $a Rituximab $2 eng 980 $x M
Počet záznamov: 1